Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
92.08
+3.69 (4.17%)
At close: Feb 27, 2026, 4:00 PM EST
92.09
+0.01 (0.01%)
After-hours: Feb 27, 2026, 5:48 PM EST
Protagonist Therapeutics Employees
Protagonist Therapeutics had 128 employees as of September 30, 2025. The number of employees increased by 2 or 1.59% compared to the same quarter last year.
Employees
128
Change
2
Growth
1.59%
Revenue / Employee
$359,500
Profits / Employee
-$1,016,789
Market Cap
5.88B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 128 | 2 | 1.59% |
| Jun 30, 2025 | 130 | 5 | 4.00% |
| Mar 31, 2025 | 124 | 0 | - |
| Dec 31, 2024 | 126 | 14 | 12.50% |
| Sep 30, 2024 | 126 | 15 | 13.51% |
| Jun 30, 2024 | 125 | 19 | 17.92% |
| Mar 31, 2024 | 124 | 21 | 20.39% |
| Dec 31, 2023 | 112 | 7 | 6.67% |
| Sep 30, 2023 | 111 | -11 | -9.02% |
| Jun 30, 2023 | 106 | -21 | -16.54% |
| Mar 31, 2023 | 103 | -19 | -15.57% |
| Dec 31, 2022 | 105 | -13 | -11.02% |
| Sep 30, 2022 | 122 | 6 | 5.17% |
| Jun 30, 2022 | 127 | 26 | 25.74% |
| Mar 31, 2022 | 122 | 39 | 46.99% |
| Dec 31, 2021 | 118 | 39 | 49.37% |
| Sep 30, 2021 | 116 | 40 | 52.63% |
| Jun 30, 2021 | 101 | 32 | 46.38% |
| Mar 31, 2021 | 83 | 3 | 3.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 991 |
| CRISPR Therapeutics AG | 393 |
| Immunovant | 362 |
| Mirum Pharmaceuticals | 355 |
| Rhythm Pharmaceuticals | 283 |
| Cogent Biosciences | 258 |
| Apogee Therapeutics | 196 |
PTGX News
- 2 days ago - CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Accesswire
- 2 days ago - Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Accesswire
- 3 days ago - Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 - Accesswire
- 6 weeks ago - Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - Accesswire
- 7 weeks ago - Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) - Business Wire
- 2 months ago - Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - Business Wire
- 4 months ago - Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Accesswire